市場調查報告書

中國的Finasteride市場分析

Investigation Report on China's Finasteride Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 910647
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Finasteride市場分析 Investigation Report on China's Finasteride Market, 2019-2023
出版日期: 2019年09月04日內容資訊: 英文 30 Pages
簡介

本報告提供中國國內的Finasteride市場相關分析,產品的概要、功效和授權情形,整體市場規模趨勢預測 (過去、今後5年份),市場價格的變化及預測,主要企業的簡介與市場佔有率等資訊彙整,為您概述為以下內容。

第1章 Finasteride的相關概念

  • Finasteride的適應症
  • 中國的Finasteride市場發展
  • 中國國內的Finasteride的相關專利和政府核准趨勢

第2章 中國國內的Finasteride的銷售量

  • Finasteride的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • Finasteride的銷售量
    • 整體銷售量
    • 各地區的銷售量
  • Finasteride的銷售量:各劑型
    • 錠劑
    • 膠囊

第3章 Finasteride的主要製造商分析

  • Finasteride的主要製造商:市場佔有率分析
    • 市場佔有率 (以金額為準)
    • 市場佔有率 (以數量為準)
  • MSD
    • 企業簡介
    • 中國的Finasteride的銷售量
  • Guangdong Rongtai Pharmaceutical Co., Ltd.
  • China Meheco Topfond Pharma Co., Ltd.
  • China Resources Saike Pharmaceutical Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

第4章 中國國內的Finasteride的價格趨勢

  • MSD (Propecia)
  • Guangdong Rongtai Pharmaceutical Co., Ltd.
  • China Meheco Topfond Pharma Co., Ltd. (Qiyue)
  • China Resources Saike Pharmaceutical Co., Ltd. (Kabo)
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

第5章 中國的Finasteride市場未來展望

  • 左右Finasteride市場發展的要素
    • 肯定的要素
    • 否定的要素
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 1909406

Description

The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases with age. BPH usually occurs after the age of 40. The incidence in men aged above 60 is higher than 50% and the incidence in men aged above 80 is 83%. Like histologic appearance, symptoms such as dysuria also increase with age. Patients with BPH account for 8% to 11% of urological inpatients, with incidence second only to that of lithangiuria. As the Chinese population ages, BPH will affect the health of more elderly people.

Finasteride is a 4-nitrosteroid hormone compound, a specific type II 5α-reductase inhibitor developed by U.S. company MSD. Since Jun. 1992 when it was approved by the FDA to be sold under trade name Proscar, it has been registered and launched in over 100 countries and regions around the world. After MSD launched Finasteride in China, many Chinese pharmaceutical companies began to develop generic Finasteride. In China, Finasteride is used to treat and control BPH and prevent urinary system events, reduce the risk of acute urinary retention and reduce the risks of transurethral resection of the prostate (TURP) and prostatectomy.

According to CRI's market survey, in 2003, Zhejiang Xianju Pharmaceutical Co., Ltd. became the first company that was approved by the CFDA to launch generic Finasteride in China. Later, other companies launched their generic Finasteride products in succession. At the end of 2018, about 20 companies were selling Finasteride in China. The brand-name Finasteride by MSD still took up a market share of more than 90%. The sales value of Finasteride kept rising after the drug was launched in China. In 2017, it reached CNY 248 million, representing a CAGR of about 2.00% from 2013 to 2017.

CRI expects that as the Chinese population ages, the incidence of BPH and the number of patients with BPH increase in China and the indications for Finasteride expand, China's Finasteride market will continue to grow.

Topics Covered:

  • Incidence of benign prostatic hyperplasia in China
  • Status of China's Finasteride market
  • Competition on China's Finasteride market
  • Major Finasteride manufacturers in China
  • Prices of Finasteride in China
  • Major factors influencing the development of China's Finasteride market
  • Prospect of China's Finasteride market from 2019 to 2023

Table of Contents

1 Relevant Concepts of Finasteride

  • 1.1 Indications for Finasteride
  • 1.2 Development of Finasteride in China
  • 1.3 Patents and Government Approval on Finasteride in China

2 Sales of Finasteride in China, 2013-2017

  • 2.1 Sales Value of Finasteride
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Finasteride
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Finasteride by Dosage Form in China, 2013-2017
    • 2.3.1 Sales of Finasteride Tablets
    • 2.3.2 Sales of Finasteride Capsules

3 Analysis on Major Finasteride Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Finasteride Manufacturers in China
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 MSD
    • 3.2.1 Enterprise Profile
    • 3.3.2 Sales of Finasteride by MSD in China
  • 3.3 Guangdong Rongtai Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Finasteride by Guangdong Rongtai Pharmaceutical Co., Ltd. In China
  • 3.4 China Meheco Topfond Pharma Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Finasteride in by China Meheco Topfond Pharma Co., Ltd. In China
  • 3.5 China Resources Saike Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Finasteride in by China Resources Saike Pharmaceutical Co., Ltd. In China
  • 3.6 Zhejiang Xianju Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Finasteride by Zhejiang Xianju Pharmaceutical Co., Ltd. In China

4 Prices of Finasteride in China, 2017-2018

  • 4.1 MSD (Propecia)
  • 4.2 Guangdong Rongtai Pharmaceutical Co., Ltd.
  • 4.3 China Meheco Topfond Pharma Co., Ltd. (Qiyue)
  • 4.4 China Resources Saike Pharmaceutical Co., Ltd. (Kabo)
  • 4.5 Zhejiang Xianju Pharmaceutical Co., Ltd.

5 Prospect of China's Finasteride Market, 2019-2023

  • 5.1 Major Factors Influencing Development of China's Finasteride Market
    • 5.1.1 Favorable Factors
    • 5.1.2 Unfavorable Factors
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Patents on Finasteride in China
  • Chart Government Approval on Finasteride in China
  • Chart Sales Value of Finasteride in China, 2013-2017
  • Chart Sales Value of Finasteride in Parts of China, 2013-2017
  • Chart Sales Volume of Finasteride in China, 2013-2017
  • Chart Sales Volume of Finasteride in Parts of China, 2013-2017
  • Chart Sales Value of Finasteride Tablets in China, 2013-2017
  • Chart Sales Volume of Finasteride Tablets in China, 2013-2017
  • Chart Sales Value of Finasteride Capsules in China, 2013-2017
  • Chart Market Share of Top 5 Finasteride Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Finasteride Manufacturers by Sales Volume in China, 2013-2017
  • Chart Profile of MSD
  • Chart Sales Value of Finasteride by MSD in China, 2013-2017
  • Chart Sales Volume of Finasteride by MSD in China, 2013-2017
  • Chart Profile of Guangdong Rongtai Pharmaceutical Co., Ltd.
  • Chart Sales Value of Finasteride by Guangdong Rongtai Pharmaceutical Co., Ltd. In China, 2013-2017
  • Chart Profile of China Meheco Topfond Pharma Co., Ltd.
  • Chart Profile of China Resources Saike Pharmaceutical Co., Ltd.
  • Chart Sales Value of Finasteride by China Resources Saike Pharmaceutical Co., Ltd. In China, 2013-2017
  • Chart Profile of Zhejiang Xianju Pharmaceutical Co., Ltd.
  • Chart Prices of Finasteride by MSD in Parts of China, 2017-2018
  • Chart Prices of Finasteride by Guangdong Rongtai Pharmaceutical Co., Ltd. In Parts of China, 2017-2018
  • Chart Prices of Finasteride by China Meheco Topfond Pharma Co., Ltd. In Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Finasteride in China, 2019-2023
Back to Top